Patheon Names Patrick Glaser Senior Vice President For Small Molecule API Business
Industry veteran to lead growing business segment for company
DURHAM, N.C.--(BUSINESS WIRE)--Patheon, a leading global provider of pharmaceutical development and manufacturing services, announced today that Patrick Glaser was appointed senior vice president of the company’s small molecule active pharmaceutical ingredient (API) business. He will be responsible for leading the transformation and expansion of the company’s API service offering in Europe and North America and will report to Lukas Utiger, president of Patheon’s drug substance services division.
Glaser joins Patheon from Teva Pharmaceutical Industries where he served as vice president of sales and marketing, API, North America and had business responsibility for more than 300 APIs. He previously held senior management, strategic marketing and business development positions at Novasep Groupe where he was president and CEO. Glaser had global responsibility for three business units: synthesis, biopharma and industrial biotech, and also managed the divestiture of non-core Novasep businesses.
“Patrick brings more than 20 years of leadership experience in the pharmaceutical industry,” said Utiger. ”We will benefit from his depth of knowledge of the industry and expertise in strategic business development as we work to continue expanding our API business.”
Glaser earned a bachelor of arts in economics from Fairleigh Dickinson University in Madison, NJ. He previously was a member of the board of directors of the Drug Chemical and Associated Technologies Association (DCAT).
About Patheon
Patheon is a leading global provider of pharmaceutical development and manufacturing services. With approximately 8,000 employees worldwide, Patheon provides a comprehensive, integrated and highly customizable set of solutions to help customers of all sizes satisfy complex development and manufacturing needs at any stage of the pharmaceutical development cycle. www.patheon.com
Contacts
Patheon
Mari Mansfield, 919-226-3137
Mari.Mansfield@Patheon.com
media@patheon.com
DURHAM, N.C.--(BUSINESS WIRE)--Patheon, a leading global provider of pharmaceutical development and manufacturing services, announced today that Patrick Glaser was appointed senior vice president of the company’s small molecule active pharmaceutical ingredient (API) business. He will be responsible for leading the transformation and expansion of the company’s API service offering in Europe and North America and will report to Lukas Utiger, president of Patheon’s drug substance services division.
Glaser joins Patheon from Teva Pharmaceutical Industries where he served as vice president of sales and marketing, API, North America and had business responsibility for more than 300 APIs. He previously held senior management, strategic marketing and business development positions at Novasep Groupe where he was president and CEO. Glaser had global responsibility for three business units: synthesis, biopharma and industrial biotech, and also managed the divestiture of non-core Novasep businesses.
“Patrick brings more than 20 years of leadership experience in the pharmaceutical industry,” said Utiger. ”We will benefit from his depth of knowledge of the industry and expertise in strategic business development as we work to continue expanding our API business.”
Glaser earned a bachelor of arts in economics from Fairleigh Dickinson University in Madison, NJ. He previously was a member of the board of directors of the Drug Chemical and Associated Technologies Association (DCAT).
About Patheon
Patheon is a leading global provider of pharmaceutical development and manufacturing services. With approximately 8,000 employees worldwide, Patheon provides a comprehensive, integrated and highly customizable set of solutions to help customers of all sizes satisfy complex development and manufacturing needs at any stage of the pharmaceutical development cycle. www.patheon.com
Contacts
Patheon
Mari Mansfield, 919-226-3137
Mari.Mansfield@Patheon.com
media@patheon.com